Murat DEMİRBİLEK, Eylem GÜVEN, Tamer ÇIRAK, Esma ALP, Mustafa TÜRK3

Targeted delivery of etoposide to osteosarcoma cells using poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles

Folic acid (FA)-functionalized poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles were prepared to enhance the delivery efficiency of the anticancer drug etoposide for the clinical treatment of osteosarcoma. PHBV nanoparticles were synthesized by emulsification/solvent evaporation technique and obtained in the size range of 200 250 nm and zeta potential range of21 and 27 mV. Encapsulation efficiency and in vitro drug release were studied. The cytotoxic, apoptotic, and necrotic effects of PHBV nanoparticles were also investigated using Saos-2 osteosarcoma cells. The results obtained in this study demonstrate that etoposideloaded and FA-functionalized PHBV nanoparticles can be successfully used for targeted treatment of osteosarcoma.

PDF

___

Baena-Aristizabal CM, Fessi H, Elaissari A, Mora-Huertas CE (2016). Biodegradable microparticles preparation by double emulsification-solvent extraction method: A systematic study. Colloid Surface A 492: 213-229.
Bajpai AK, Mishra A (2005). Preparation and characterization of tetracycline-loaded interpenetrating polymer networks of carboxymethyl cellulose and poly(acrylic acid): water sorption and drug release study. Polym Int 54: 1347-1356.
Decuzzi P, Ferrari M (2007). The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. Biomaterials 28: 2915-2922.
Dhanaraju MD, Sathyamoorthy N, Sundar VD, Suresh C (2010). Preparation of poly (epsilon-caprolactone) microspheres containing etoposide by solvent evaporation method. Asian Journal of Pharmaceutical Science 5: 114-122.
Gassner F, Owen AJ (1996). Some properties of poly(3- hydroxybutyrate)-poly(3-hydroxyvalerate) blends. Polym Int 39: 215-219.
Hande KR (1998). Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34: 1514-1521.
Jabir NR, Tabrez S, Ashraf GM, Shakil S, Damanhouri GA, Kamal MA (2012). Nanotechnology-based approaches in anticancer research. Int J Nanomedicine 7: 4391-4408.
Kilicay E, Demirbilek M, Turk M, Guven E, Hazer B, Denkbas EB (2011). Preparation and characterization of poly(3- hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHX) based nanoparticles for targeted cancer therapy. Eur J Pharm Sci 44: 310-320.
Low PS, Kularatne SA (2009). Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 13: 256-262.
Lu XY, Zhang YL, Wang L (2010). Preparation and in vitro drug-release behavior of 5-fluorouracil-loaded poly(hydroxybutyrate-cohydroxyhexanoate) nanoparticles and microparticles. J Appl Polym Sci 116: 2944-2950.
Moongkarndi P, Kosem N, Kaslungka S, Luanratana O, Pongpan N, Neungton N (2004). Antiproliferation, antioxidation and induction of apoptosis by Garcinia mangostana (mangosteen) on SKBR3 human breast cancer cell line. J Ethnopharmacol 90: 161-166.
Park EK, Lee SB, Lee YM (2005). Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials 26: 1053-1061.
Parveen S, Sahoo SK (2008). Polymeric nanoparticles for cancer therapy. J Drug Target 16: 108-123.
Patil S, Sandberg A, Heckert E, Self W, Seal S (2007). Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials 28: 4600-4607.
Qian C, McClements DJ (2011). Formation of nanoemulsions stabilized by model food-grade emulsifiers using highpressure homogenization: Factors affecting particle size. Food Hydrocolloid 25: 1000-1008.
Schwartz CL, Garlick R, Teot L, Krailo M, Chen ZJ, Goorin A, Grier HE, Bernstein ML, Meyers P (2007). Multiple drug resistance in osteogenic sarcoma: INT0133 from the Childrens Oncology Group. J Clin Oncol 25: 2057-2062.
Tan CP, Nakajima M (2005). Beta-carotene nanodispersions: preparation, characterization and stability evaluation. Food Chem 92: 661-671.
Tcholakova S, Denkov ND, Sidzhakova D, Ivanov IB, Campbell B (2003). Interrelation between drop size and protein adsorption at various emulsification conditions. Langmuir 19: 5640-5649.
van Engeland M, Nieland LJW, Ramaekers FCS, Schutte B, Reutelingsperger CPM (1998). Annexin V-affinity assay: A review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31: 1-9.
van Meerloo J, Kaspers GJ, Cloos J (2011). Cell sensitivity assays: the MTT assay. Methods Mol Biol 731: 237-245.
Vasir JK, Labhasetwar V (2005). Targeted drug delivery in cancer therapy. Technol Cancer Res T 4: 363-374.
Vilos C, Morales FA, Solar PA, Herrera NS, Gonzalez-Nilo FD, Aguayo DA, Mendoza HL, Comer J, Bravo ML, Gonzalez PA et al. (2013). Paclitaxel-PHBV nanoparticles and their toxicity to endometrial and primary ovarian cancer cells. Biomaterials 34: 4098-4108.
Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar-Graney K, Shmookler B, Malawer MM (2002). Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician 65: 1123-1132.
Xu FZ, Zhao TQ, Yang T, Dong LL, Guan XY, Cui XJ (2016). Fabrication of folic acid functionalized pH-responsive and thermosensitive magnetic chitosan microcapsules via a simple sonochemical method. Colloid Surface A 490: 22-29.
Yang R, Kolb EA, Qin J, Chou A, Sowers R, Hoang B, Healey JH, Huvos AG, Meyers PA, Gorlick R (2007). The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin Cancer Res 13: 2557-2567.
Yu MK, Park J, Jon S (2012). Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2: 3-44.
Zhang C, Zhao LQ, Dong YF, Zhang XY, Lin J, Chen Z (2010). Folatemediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery. Eur J Pharm Biopharm 76: 10-16.
Zhang TC, Chen JN, Zhang Y, Shen Q, Pan WS (2011). Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci 43: 174-179.